Latest News
Lucid Diagnostics Inc.
- Penny stocks gain attention as oil prices top $100, spotlighting innovative firms like Kraig Biocraft and Lucid Diagnostics.
- Medicare Begins Reimbursing Lucid Diagnostics’ EsoGuard Test
- Lucid Diagnostics Closes $15M Financing, Receives Medicare Reimbursement for EsoGuard Test
- PAVmed subsidiary Lucid Diagnostics raises $15 million in preferred stock sale
- Lucid Diagnostics Raises $15 Million Through Series C Preferred Stock Offering
- Lucid Diagnostics raises $15M as Medicare begins paying for its cancer test
- Form 8K Lucid Diagnostics Inc For: 22 October By Investing.com
- Lucid Diagnostics raises $15 million through Series C preferred stock sale
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
- Medicare has begun paying $1,938.01 for each of Lucid’s esophageal DNA tests.
- Lucid Diagnostics Receives Nasdaq Notice for Sub-$1 Bid Price, Faces Compliance Deadline
- Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Headlines from the last 30 days, linking to the original publishers. See all market news →